Astal Laboratories Ltd
Astal Laboratories Ltd (ASTALLTD) last reported results for the quarter ended Jun 2026, with sales of ₹101 crore and net profit of ₹9.42 crore. The stock last traded at ₹68.1, a market capitalisation of ₹298 crore, on a P/E of 20.3. Over the past 52 weeks the stock has ranged between ₹60.4 and ₹103. Figures are as of 9 Oct 2026 and are not real time.
Astal Laboratories Ltd share price and key metrics
- Current price
- ₹68.1
- Market cap
- ₹298 cr
- Stock P/E
- 20.3
- Book value
- ₹79.1
- ROE
- 7.96%
- ROCE
- 9.15%
- Dividend yield
- 0.00%
- 52w high / low
- 103/60.4
Metrics as of 9 Oct 2026. Not real time.
Track Astal Laboratories Ltd
Cruxal reads every Astal Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Astal Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 289%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 65%
- 10 Years
- 9%
- 5 Years
- 44%
- 3 Years
- 27%
- 1 Year
- -31%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 8%
Astal Laboratories Ltd quarterly results
| ₹ crore | Mar 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 23.47 | 52.24 | 134 | 101 |
| Expenses | 19.29 | 48.69 | 124 | 88.69 |
| Operating profit | 4.18 | 3.55 | 10.19 | 12.25 |
| OPM % | 17.81% | 6.80% | 7.60% | 12.14% |
| Other income | 0.04 | 0.04 | 0.1 | 0.14 |
| Interest | 0.27 | 0.33 | 1.09 | 1.18 |
| Depreciation | 0.1 | 0.12 | 0.86 | 0.86 |
| Profit before tax | 3.85 | 3.14 | 8.34 | 10.35 |
| Tax % | 28.57% | 24.52% | 7.91% | 8.99% |
| Net profit | 2.74 | 2.36 | 7.68 | 9.42 |
| EPS (₹) | 2.79 | 2.19 | 1.82 | 2.15 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Astal Laboratories Ltd annual results
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 64 | 250 |
| Operating profit | 13 | 21 |
| OPM % | 20% | 8% |
| Net profit | 9 | 15 |
| EPS (₹) | 9.08 | 3.48 |
TTM is the trailing twelve months to the most recent quarter.
Astal Laboratories Ltd balance sheet
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 10 | 42 |
| Reserves | 26 | 292 |
| Borrowings | 13 | 49 |
| Other liabilities | 14 | 136 |
| Total liabilities | 63 | 519 |
| Fixed assets | 11 | 64 |
| CWIP | -0 | -0 |
| Investments | -0 | 203 |
| Other assets | 52 | 251 |
| Total assets | 63 | 519 |
As reported by the company. Total assets equal total liabilities by construction.
Astal Laboratories Ltd cash flow
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operations | -13 | -18 |
| Cash from investing | -8 | -2 |
| Cash from financing | 3 | 3 |
| Net cash flow | -17 | -17 |
| Free cash flow | -18 | -19 |
| CFO / operating profit | -96% | -80% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Astal Laboratories Ltd operating ratios
| Per year | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | — | 9% |
| Debtor days | 157 | 229 |
| Inventory days | 112 | 112 |
| Days payable | 82 | 206 |
| Cash conversion cycle | 187 | 135 |
| Working capital days | 97 | 113 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Astal Laboratories Ltd shareholding pattern
Promoters held 4.53% at Jun 2026, down from 19.93% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 19.93% | 19.93% | 19.93% | 19.93% | 18.19% | 18.19% | 4.70% | 4.53% |
| Public | 80.07% | 80.07% | 80.07% | 80.08% | 81.81% | 81.79% | 95.29% | 95.46% |
| No. of shareholders | 1,629 | 1,925 | 2,302 | 2,721 | 2,899 | 2,926 | 3,065 | 3,274 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Astal Laboratories Ltd corporate filings
- Astal Laboratories' 33rd AGM Voting Results Indicate Near-Universal Support for ResolutionsAGM/EGMmedium impact
Cruxal's analysis: Astal Laboratories Limited reported overwhelmingly positive voting outcomes for all…
Read the full analysis - Submission of Trading window closure Intimation.Insider Trading / SASTlow impact
- Astal Laboratories approves appointment of internal and secretarial auditors for FY 2026-27, with no immediate financial impactCompany Updatelow impact
Cruxal's analysis: Astal Laboratories Limited has announced the appointment of M/s Avnesh Jain & Co. as Cost…
Read the full analysis - Astal Laboratories Limited appoints Ms. Ambika Kedia as Company Secretary, effective 28th September 2026Company Updatelow impact
Cruxal's analysis: Astal Laboratories Limited has announced the appointment of Ms. Ambika Kedia as Company…
Read the full analysis - Submission of outcome of 33rd Annual General Meeting.AGM/EGMmedium impact
- Astal Laboratories Ltd submits intimation regarding Code of Conduct under SEBI (PIT) RegulationsCompany Updatelow impact
Cruxal's analysis: Astal Laboratories Ltd has filed a routine compliance intimation regarding its Code of…
Read the full analysis - Astal Laboratories Limited Announces 33rd Annual General Meeting and E-Voting ScheduleCompany Updatelow impact
Cruxal's analysis: Astal Laboratories Limited has issued a formal intimation regarding its 33rd Annual…
Read the full analysis - Astal Laboratories Limited schedules 33rd Annual General Meeting for September 29, 2026Company Updatelow impact
Cruxal's analysis: Astal Laboratories Limited has issued a formal notice for its 33rd Annual General Meeting…
Read the full analysis - Astal Laboratories Limited Announces 33rd Annual General Meeting Scheduled for September 29, 2026AGM/EGMlow impact
Cruxal's analysis: Astal Laboratories Limited has issued a formal notice for its 33rd Annual General Meeting…
Read the full analysis - Astal Laboratories Ltd submits Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Astal Laboratories Ltd has filed its Annual Report for the financial year ended March 31…
Read the full analysis - Astal Laboratories Limited announces 33rd Annual General Meeting for September 29, 2026AGM/EGMlow impact
Cruxal's analysis: Astal Laboratories Limited has formally intimated the BSE regarding the scheduling of its…
Read the full analysis - Astal Laboratories Limited appoints M/s Avnesh Jain & Co. as Cost Auditor for FY 2026-27Company Updatelow impact
Cruxal's analysis: Astal Laboratories Limited has formally announced the appointment of M/s Avnesh Jain &…
Read the full analysis - Astal Laboratories Limited schedules Board Meeting for September 4, 2026, to approve 33rd AGM notice and FY26 Board ReportBoard Meetinglow impact
Cruxal's analysis: Astal Laboratories Limited has issued a formal intimation under Regulation 29 of SEBI…
Read the full analysis - Astal Laboratories Limited Reports Q1 FY2027 Financial Results with Significant Revenue and Profit GrowthCompany Updatehigh impact
Cruxal's analysis: Astal Laboratories Limited has released its unaudited standalone and consolidated…
Read the full analysis - Astal Laboratories Ltd submits Statement of Deviation or Variation for fund utilizationCompany Updatelow impact
Cruxal's analysis: Astal Laboratories Ltd has filed a Statement of Deviation or Variation regarding the…
Read the full analysis - Astal Laboratories Reports Strong Q1 FY27 Financials with Consolidated Net Profit of 9.42 croreResulthigh impact
Cruxal's analysis: Astal Laboratories Limited has declared its unaudited financial results for the quarter…
Read the full analysis - Astal Laboratories Reports Strong Q1 FY27 Financials with Consolidated Net Profit of 9.42 croreBoard Meetinghigh impact
Cruxal's analysis: Astal Laboratories Limited has announced its unaudited financial results for the quarter…
Read the full analysis - Astal Laboratories Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Astal Laboratories Limited has formally intimated the BSE regarding a Board Meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.